9 stories mentioning VRDNUpdated 7d ago
Every FINWIRES story that references VRDN, newest first.
Viridian Therapeutics (VRDN) has an average rating of buy and mean price target of $36.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $21.17, Change: $+0.10, Percent Change: +0.47%
Viridian Therapeutics' (VRDN) Lumvoa therapy for thyroid eye disease, or TED, could start generating more meaningful revenue in 2027 and then reach peak levels in 2028, RBC Capital Markets said in a Monday note.RBC estimates revenue from Lumvoa in 2026 is expected to be minimal at about $10 million, with a more conservative payer ramp, and then increase to $243 million in 2027, according to the note. Patient conversion into revenue in 2027 will be spurred by payer dynamics, J-codes, and prior authorization periods, the brokerage added.Viridian management expects a permanent J-code for the therapy in Q1 2027 and estimates coverage to reach critical mass in six to nine months, RBC said.The brokerage also noted that Viridian priced Lumvoa at par with rival therapy Tepezza, and that the two treatments could lead the TED market as a duopoly in the coming years.RBC Capital Markets raised its price target on Viridian Therapeutics to $35 from $34, with an outperform rating.Price: $18.78, Change: $-0.01, Percent Change: -0.05%
Viridian Therapeutics (VRDN) has an average rating of buy and mean price target of $35.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Viridian Therapeutics (VRDN) has an average rating of buy and mean price target of $32.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $18.47, Change: $+0.57, Percent Change: +3.18%
Viridian Therapeutics (VRDN) has an average rating of buy and mean price target of $32.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $18.98, Change: $+1.08, Percent Change: +6.02%
Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) advancing by 0.3%.BridgeBio Pharma (BBIO) stock was up 3.8% after the company said it has met the primary endpoint in a late-stage trial of the oral drug infigratinib, for the treatment of children living with achondroplasia, or bone dwarfism.Viridian Therapeutics (VRDN) shares were up more than 8% after the company said Lumvoa received approval from the US Food and Drug Administration to treat thyroid eye disease, an autoimmune disease.Zymeworks (ZYME) has signed a definitive agreement to acquire Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 5% and Theravance Biopharma stock fell 3.5% pre-bell.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1%, and the actively traded Invesco QQQ Trust (QQQ) advanced 1.3% in Monday's premarket activity, amid optimism around renewed diplomatic efforts between Washington and Tehran.US stock futures were also higher, with S&P 500 Index futures up 0.8%, Dow Jones Industrial Average futures advancing 0.4%, and Nasdaq futures gaining 1% before the start of regular trading.The Dallas Fed manufacturing survey for June will be released at 10:30 am ET.In premarket action, bitcoin was up by 0.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.1% higher, Ether ETF (EETH) increased by 0.9%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined by 0.2%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.5%, the Vanguard Health Care Index Fund (VHT) was up 0.5%, while the iShares US Healthcare ETF (IYH) gained by 1.2%. The iShares Biotechnology ETF (IBB) was 0.3% higher.Viridian Therapeutics (VRDN) stock was up 8.9% premarket after the company said that its Lumvoa medicine received approval from the US Food and Drug Administration to treat thyroid eye disease, an autoimmune disease.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.5%, while the Vanguard Industrials Index Fund (VIS) was up 6% and the iShares US Industrials ETF (IYJ) was inactive.Rocket Lab (RKLB) stock was up more than 10% before the opening bell after the company agreed to acquire Iridium Communications (IRDM) in a cash-and-stock deal valuing the satellite operator at an enterprise value of about $8 billion.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.7%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.1% lower.Robinhood Markets (HOOD) shares were 2% higher before the opening bell, extending gains from a 5.6% rise on Friday. Goldman Sachs lifted its price target on the company to $121 from $108, while maintaining a buy rating.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.1%, and the iShares US Technology ETF (IYW) was 1.2% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 2%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained by 1.3%, while the iShares Semiconductor ETF (SOXX) rose by 0.9%.Nvidia (NVDA) shares were up 0.8% in premarket activity, after a 1.6% fall at the previous close. Firmus Technologies said over the weekend that Nvidia will supply up to 170,000 artificial intelligence accelerators for its planned AI factory campus in Batam, Indonesia.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was marginally higher, and the iShares US Consumer Staples ETF (IYK) fell 1.5%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained by 0.6%. The VanEck Retail ETF (RTH) was up 0.4, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% higher.Amazon's (AMZN) shares were up nearly 1% pre-bell after gaining 2.5% at Friday's close. Reuters reported over the weekend that the retailer's Prime Day discounts generated more than $26.4 billion in sales from June 23 to June 26, a 9.3% year-over-year increase.EnergyThe iShares US Energy ETF (IYE) was down 0.1%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.2%.Eni (E) stock was up more than 1% before market open after the company said it has started enhanced gas production off the coast of Libya, in partnership with Libyan National Oil.CommoditiesFront-month US West Texas Intermediate crude oil gained by 1.2% to $70.07 per barrel on the New York Mercantile Exchange. Natural gas retreated by 2.3% to $3.20 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.6%, while the United States Natural Gas Fund (UNG) was 3% lower.Gold futures for July were down by 1.1% to $4,051.50 an ounce on the Comex. Silver futures retreated by 1.9% to $58.53 an ounce. SPDR Gold Shares (GLD) was down by 0.6%, and the iShares Silver Trust (SLV) was 0.8% lower.
Viridian Therapeutics (VRDN) said Monday that Lumvoa received approval from the US Food and Drug Administration to treat thyroid eye disease, an autoimmune disease.The company said it plans to launch Lumvoa immediately, and physicians can prescribe Lumvoa from Tuesday.Viridian said that Lumvoa was approved by the FDA under Priority Review and was supported by data from the THRIVE and THRIVE-2 phase 3 clinical trials.Shares of the company were up 14% in Monday's premarket activity.Price: $20.41, Change: $+2.51, Percent Change: +14.02%
Viridian Therapeutics (VRDN) has an average rating of Buy and mean price target of $33.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $18.75, Change: $+4.69, Percent Change: +33.36%
